Lexicon Pharmaceuticals, Inc. (LXRX) Revenue History
Annual and quarterly revenue from 1999 to present
LXRX Revenue Over Time (1999–2025)
LXRX Revenue Growth History
13 of 26 years with positive growth- FY1999 revenue growth
- N/A
- FY2000 revenue growth
- +207.6%
- FY2001 revenue growth
- +2013.5%
- FY2002 revenue growth
- -88.5%
- FY2003 revenue growth
- +21.7%
- FY2004 revenue growth
- +44.1%
- FY2005 revenue growth
- +22.6%
- FY2006 revenue growth
- -3.8%
- FY2007 revenue growth
- -31.2%
- FY2008 revenue growth
- -35.5%
- FY2009 revenue growth
- -66.9%
- FY2010 revenue growth
- -54.1%
- FY2011 revenue growth
- -62.3%
- FY2012 revenue growth
- -41.1%
- FY2013 revenue growth
- +104.0%
- FY2014 revenue growth
- +928.5%
- FY2015 revenue growth
- +468.9%
- FY2016 revenue growth
- -35.9%
- FY2017 revenue growth
- +8.4%
- FY2018 revenue growth
- -30.0%
- FY2019 revenue growth
- +409.5%
- FY2020 revenue growth
- -92.5%
- FY2021 revenue growth
- -98.8%
- FY2022 revenue growth
- -53.4%
- FY2023 revenue growth
- +766.2%
- FY2024 revenue growth
- +2481.5%
- FY2025 revenue growth
- +60.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $21.1M | +1572.1% |
| Q4 2025 | $5.5M | -79.3% |
| Q3 2025 | $14.2M | +710.4% |
| Q2 2025 | $28.9M | +1652.6% |
| Q1 2025 | $1.3M | +11.7% |
| Q4 2024 | $26.6M | +3682.6% |
| Q3 2024 | $1.8M | +980.2% |
| Q2 2024 | $1.6M | +419.6% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
LXRX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
LXRX Revenue Analysis (1999–2025)
Current Revenue & Growth
As of June 23, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) generated trailing twelve-month (TTM) revenue of $69.6 million, reflecting explosive growth of +1572.1% year-over-year. The most recent quarter (Q1 2026) recorded $21.1 million in revenue, up 284.2% sequentially.
Historical Growth Trajectory
LXRX's 5-year compound annual growth rate (CAGR) stands at +15.7%, indicating consistent double-digit revenue growth. The 3-year CAGR of +610.3% exceeds the 5-year average, indicating an acceleration in the most recent period. Lexicon Pharmaceuticals, Inc.'s highest annual revenue of $322.1 million was recorded in 2019.
Revenue by Segment
LXRX's revenue is primarily driven by License (91%), and Product (9%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ARDX (+18.2% YoY), CORT (+12.2% YoY), and INVA (+13.6% YoY) — LXRX has outperformed the peer group in revenue growth. Compare LXRX vs ARDX →
LXRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LXRXCurrent | $70M | +1572.1% | +15.7% | -98.2% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
LXRX Historical Revenue Data (1999–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $49.8M | +60.2% | $49.5M | 99.4% | $-48,911,000 | -98.2% |
| 2024 | $31.1M | +2481.5% | $30.5M | 98.0% | $-197,117,000 | -634.2% |
| 2023 | $1.2M | +766.2% | $-57,768,000 | -4798.0% | $-171,750,000 | -14265.0% |
| 2022 | $139K | -53.4% | $-52,377,000 | -37681.3% | $-100,760,000 | -72489.2% |
| 2021 | $298K | -98.8% | $-54,748,000 | -18371.8% | $-87,090,000 | -29224.8% |
| 2020 | $24.0M | -92.5% | $22.1M | 92.0% | $-47,800,000 | -199.2% |
| 2019 | $322.1M | +409.5% | $318.8M | 99.0% | $141.4M | 43.9% |
| 2018 | $63.2M | -30.0% | $60.7M | 96.1% | $-103,279,000 | -163.4% |
| 2017 | $90.3M | +8.4% | $88.4M | 97.9% | $-136,681,000 | -151.3% |
| 2016 | $83.3M | -35.9% | $-80,636,000 | -96.8% | $-137,155,000 | -164.6% |
| 2015 | $130.0M | +468.9% | $34.8M | 26.8% | $1.5M | 1.1% |
| 2014 | $22.9M | +928.5% | $-66,425,000 | -290.6% | $-100,366,000 | -439.2% |
| 2013 | $2.2M | +104.0% | $-87,460,000 | -3936.1% | $-102,371,000 | -4607.2% |
| 2012 | $1.1M | -41.1% | $-81,485,000 | -7482.6% | $-108,415,000 | -9955.5% |
| 2011 | $1.8M | -62.3% | $1.8M | 100.0% | $-114,095,000 | -6170.6% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
Is LXRX's revenue growth accelerating or slowing?
LXRX revenue growth is accelerating. TTM revenue reached $70M, up +1572.1% year-over-year — ahead of the 5-year CAGR of +15.7%. This indicates the business is expanding faster than its historical baseline.
What is LXRX's revenue history from 1999 to 2026?
Lexicon Pharmaceuticals, Inc. (LXRX) revenue history spans 1999 to 2026. TTM revenue as of 2026 is $70M, growing at +1572.1% YoY. The 5-year CAGR is +15.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is LXRX's long-term revenue growth rate (CAGR)?
Lexicon Pharmaceuticals, Inc.'s 5-year revenue CAGR of +15.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +1572.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LXRX.
Why does LXRX's quarterly revenue fluctuate?
LXRX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Lexicon Pharmaceuticals, Inc.'s revenue data from 1999 to 2026 shows full historical quarterly detail on this page.
How is LXRX's revenue distributed by segment?
LXRX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does LXRX's revenue compare to industry peers?
Lexicon Pharmaceuticals, Inc. (LXRX) with TTM revenue of $70M and +1572.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.